Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
[8] performed a systematic review aimed at comparing the risk of RGC in GLP-1RA users and non-users undergoing endoscopy
Retatrutide is in active Phase 3 clinical development under Eli Lilly's TRIUMPH programme
Retatrutide activates GLP-1, GIP, and glucagon receptors, offering a broader approach to weight loss and metabolic health
Competitive Landscape of Obesity GLP-1 Market The global GLP-1 and obesity drug landscape is entering a transformative phase as patent protections for semaglutide near expiry in key markets such as India and China by 2026
US$ 22.06
US$ 21.44
US$ 22.38
US$ 29.96
US$ 28.22
US$ 22.93
US$ 23.17
